Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10920192 | Radiotherapy and Oncology | 2005 | 8 Pages |
Abstract
The clinical outcome illustrates excellent LRC rates at 5-years for BT (85%), as well as for S (82%). The relatively low 55% LRC rate at 5-years for EBRT probably reflects a negative selection of patients. It is of interest that the total mean costs of patients alive with no evidence of disease is least for the BT-group: â¬15,101 as opposed to â¬25,288 (S) and â¬18,674 (EBRT). Main underlying cause for the high costs with S as opposed to RT alone is the number of associated clinical admission days, not only during primary treatment, but also at relapse. This might be taken into consideration when treating these patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Wideke Nijdam, Peter Levendag, Inge Noever, Carin Uyl-de Groot, Michel van Agthoven,